# OnCo record nct07230106 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07230106/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07230106", "NCT07230106" ;
  schema:name "A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer"@en ;
  schema:description "A phase 2 trial of HS-20093, Rezvilutamide, Abiraterone acetate in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07230106/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07230106> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-12-08" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/rezvilutamide/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .